Developer docs
API playgroundTry for free, no card

Search company profiles

CasZyme

Full company profile

uuid0007awz

Namestring
CasZyme
Legal namestring
Caszyme, LLC
Websiteurl
caszyme.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CasZyme is a Vilnius, Lithuania-based biotechnology company founded in 2017 that develops CRISPR-Cas molecular tools, with a core focus on ultra-compact Cas12l nucleases optimized for therapeutic delivery via adeno-associated viruses (AAVs). The company's technology platform spans bioinformatics and AI-driven discovery of novel nucleases from metagenomic databases, rational design and directed evolution of protein variants, comprehensive biochemical characterization, and mRNA synthesis and optimization services. CasZyme serves five application areas: therapeutics, agri-tech, diagnostics, research tools, and industrial biotech, providing both custom CRISPR solution development and licensing of proprietary technologies such as Cas12l to enterprise partners including Corteva Agriscience and BetterSeeds.

The company monetizes primarily through professional services (custom CRISPR solution development, nuclease characterization, protein evolution, mRNA services) and licensing/royalty arrangements with pharmaceutical, agricultural, and biotech clients. Its go-to-market is B2B and partner-centric, with no traditional distribution channels — relationships are driven by direct enterprise sales and strategic licensing deals, supplemented by participation in industry conferences (e.g., ASGCT) and EU-funded collaborative R&D consortia (Eurostars/EUREKA projects including UNCOVER, CREATIVE, SMART, and WiFIX). The firm is privately held as an LLC, employs 11-50 people, and has sustained operations through a combination of grant funding, service revenue, and licensing income rather than disclosed venture capital rounds.

Recent strategic activity includes the 2026 collaboration with BetterSeeds and Corteva Agriscience to combine Cas12l nucleases with viral delivery platforms for crop gene editing, the EUR 1M WiFIX Eurostars grant for nucleic acid therapeutic delivery, publication of peer-reviewed Cas12l validation, and ongoing expansion into diagnostics via the UNCOVER platform. The competitive position rests on proprietary ultra-compact nuclease IP, founder provenance as CRISPR-Cas9 pioneers, and an integrated discovery-to-characterization service stack, though revenue concentration on a small number of named enterprise partners and absence of disclosed funding rounds indicate an early-stage commercial profile.

Short descriptiontext

CasZyme is a Vilnius-based CRISPR biotech developing ultra-compact Cas12l nucleases and custom gene editing services for pharmaceutical, agricultural, and diagnostics clients, monetizing through licensing deals and bespoke R&D partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVilnius, Lithuania
HQ citystring
Vilnius
HQ countrystring
Lithuania
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, Cas nuclease discovery, protein engineering services, mRNA synthesis optimization, molecular biology tools
Industry5 codes
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
CRISPR Gene Editing Tools and Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Custom CRISPR Solutions Development
TypeProfessional Services
Description

CasZyme provides custom CRISPR solutions to partners, developing tailored gene editing tools and services. The company combines deep experience and a dynamic platform to deliver world-class CRISPR solutions to partners across healthcare and sustainability sectors.

caszyme.com
2Licensing of Proprietary Technologies
TypeLicensing Royalties
Description

CasZyme licenses its Cas12l nucleases and related technologies to partners such as Corteva Agriscience, enabling viral delivery of gene edits directly into crops.

caszyme.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CasZyme develops and provides custom CRISPR-Cas molecular tools and solution development services, centered on its proprietary ultra-compact Cas12l nuclease platform optimized for therapeutic delivery via adeno-associated viruses and for viral vector delivery in crops. The company combines deep bioinformatics/AI-driven discovery, protein engineering (rational design and directed evolution), biochemical characterization, and mRNA synthesis/optimization to deliver tailored gene editing solutions to partners in therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Revenue is generated through professional service engagements and licensing of proprietary Cas12l technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 50%+ reduction in time and cost compared to traditional tissue culture approaches
Product overview1 text field

CasZyme operates as a CRISPR technology platform company offering specialized services and proprietary nucleases. The core product is the Cas12l Platform featuring ultra-compact Cas12l nucleases optimized for therapeutic delivery. The service portfolio includes Custom CRISPR Solutions (end-to-end development from bioinformatics through verification), Nuclease Expertise (screening, purification, biochemical analysis), mRNA Synthesis and Optimization, and Protein Evolution. These offerings support five application areas: Therapeutics, Agri-Tech, Diagnostics, Research Tools, and Industrial Biotech. The company leverages over 15 years of CRISPR expertise to deliver market-ready products through a flexible, diverse platform.

Product and service1 record
1Cas12l Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-13
Description

CasZyme and BetterSeeds announced a collaboration to overcome the tissue culture bottleneck in plant gene editing by combining CasZyme's ultra-compact Cas12l nucleases with BetterSeeds' viral vector-based EDGE delivery platform. The partnership aims to eliminate or substantially reduce reliance on tissue culture, which is time-consuming, costly, and genotype-dependent, potentially cutting time and cost by more than 50% compared to traditional approaches.

2Corteva Agriscience
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-13
Description

Corteva Agriscience has licensed Cas12l to both CasZyme and BetterSeeds, enabling viral delivery of gene edits directly into crops. This licensing arrangement makes CRISPR technology more accessible to a broader range of seed companies.

agtechnavigator.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Part of the EUREKA-Eurostars 3 project UNCOVER (Universal CRISPR-based Detection Platform for Versatile and Rapid Diagnostics) along with nSAGE and other partners. CasZyme is a member of the Vilnius University Consortium in the 'Implementation of Mission-Driven Science and Innovation Programmes' project focused on Innovations for Health.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on CasZyme's website with logo displayed among other partner organizations. Vilnius University is also part of the consortium in EU grants.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Metagenomi uses AI and metagenomic databases to discover novel CRISPR nuclease systems for therapeutic gene editing — the same core discovery thesis and methodology as CasZyme, but focused on human therapeutics development.

TypeDirect peer
Description

ToolGen is a Korea-based CRISPR tools company that discovers and licenses novel Cas nucleases for therapeutic and agricultural gene editing, overlapping with CasZyme's nuclease platform and licensing model.

TypeDirect peer
Description

Caribou Biosciences is a CRISPR platform company developing Cas nuclease-derived tools for both therapeutic and non-therapeutic applications, sharing CasZyme's platform-tools orientation and multi-vertical licensing approach.

TypeBroad incumbent
Description

Intellia is a clinical-stage gene editing company developing CRISPR-based therapeutics using its own proprietary nucleases; it represents a well-funded incumbent competing for the same therapeutic licensing and partnership opportunities CasZyme targets.

TypeBroad incumbent
Description

Editas Medicine is a clinical-stage gene editing company with proprietary Cas9 and Cas12a programs across therapeutic areas, operating as a broad incumbent in the same CRISPR therapeutics space as CasZyme.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Cas9-based therapy (Casgevy), representing a well-capitalized incumbent in the therapeutic CRISPR market where CasZyme's nuclease IP could be licensed.

TypeBroad incumbent
Description

Beam Therapeutics develops base editing and prime editing therapeutics using proprietary enzymes, an adjacent gene editing modality that competes for the same therapeutic partnerships and licensing economics CasZyme targets.

TypeBroad incumbent
Description

NEB is a leading life science reagents and enzyme company that distributes research-use CRISPR tools, listed as a CasZyme partner. It represents a broad incumbent in the same research tools and nuclease distribution market.

TypeBroad incumbent
Description

Thermo Fisher is a global life science tools and reagents giant with extensive gene editing and CRISPR product lines, listed as a CasZyme partner. It serves as a broad incumbent across the same customer base.

TypeEmerging player
Description

Inscripta developed a CRISPR platform for gene editing and was acquired by Element Biosciences; it represents an emerging peer in CRISPR tools commercialization, with comparable nucleic acid manipulation focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CasZyme

CRISPR Gene Editing Tools and Servicescaszyme.com

CasZyme is a Vilnius-based CRISPR biotech developing ultra-compact Cas12l nucleases and custom gene editing services for pharmaceutical, agricultural, and diagnostics clients, monetizing through licensing deals and bespoke R&D partnerships.

What CasZyme does

CasZyme is a Vilnius, Lithuania-based biotechnology company founded in 2017 that develops CRISPR-Cas molecular tools, with a core focus on ultra-compact Cas12l nucleases optimized for therapeutic delivery via adeno-associated viruses (AAVs). The company's technology platform spans bioinformatics and AI-driven discovery of novel nucleases from metagenomic databases, rational design and directed evolution of protein variants, comprehensive biochemical characterization, and mRNA synthesis and optimization services. CasZyme serves five application areas: therapeutics, agri-tech, diagnostics, research tools, and industrial biotech, providing both custom CRISPR solution development and licensing of proprietary technologies such as Cas12l to enterprise partners including Corteva Agriscience and BetterSeeds.

The company monetizes primarily through professional services (custom CRISPR solution development, nuclease characterization, protein evolution, mRNA services) and licensing/royalty arrangements with pharmaceutical, agricultural, and biotech clients. Its go-to-market is B2B and partner-centric, with no traditional distribution channels — relationships are driven by direct enterprise sales and strategic licensing deals, supplemented by participation in industry conferences (e.g., ASGCT) and EU-funded collaborative R&D consortia (Eurostars/EUREKA projects including UNCOVER, CREATIVE, SMART, and WiFIX). The firm is privately held as an LLC, employs 11-50 people, and has sustained operations through a combination of grant funding, service revenue, and licensing income rather than disclosed venture capital rounds.

Recent strategic activity includes the 2026 collaboration with BetterSeeds and Corteva Agriscience to combine Cas12l nucleases with viral delivery platforms for crop gene editing, the EUR 1M WiFIX Eurostars grant for nucleic acid therapeutic delivery, publication of peer-reviewed Cas12l validation, and ongoing expansion into diagnostics via the UNCOVER platform. The competitive position rests on proprietary ultra-compact nuclease IP, founder provenance as CRISPR-Cas9 pioneers, and an integrated discovery-to-characterization service stack, though revenue concentration on a small number of named enterprise partners and absence of disclosed funding rounds indicate an early-stage commercial profile.

CasZyme firmographics

Firmographics
Name
CasZyme
Legal name
Caszyme, LLC
Website
https://caszyme.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
CasZyme is a Vilnius-based CRISPR biotech developing ultra-compact Cas12l nucleases and custom gene editing services for pharmaceutical, agricultural, and diagnostics clients, monetizing through licensing deals and bespoke R&D partnerships.
Ownership category
akta.pro rank

CasZyme industry classification

Industry
Product category
CRISPR Gene Editing Tools and Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • CRISPR gene editing
  • Cas nuclease discovery
  • Protein engineering services
  • MRNA synthesis optimization
  • Molecular biology tools

Where CasZyme is headquartered

Location

Headquarters

HQ city
Vilnius
HQ country
Lithuania
HQ region
Europe

Offices1 record

Markets served

CasZyme business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Custom CRISPR Solutions Development: CasZyme provides custom CRISPR solutions to partners, developing tailored gene editing tools and services. The company combines deep experience and a dynamic platform to deliver world-class CRISPR solutions to partners across healthcare and sustainability sectors.
  2. Licensing of Proprietary Technologies: CasZyme licenses its Cas12l nucleases and related technologies to partners such as Corteva Agriscience, enabling viral delivery of gene edits directly into crops.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

CasZyme product offering

Product offering

Core offering

CasZyme develops and provides custom CRISPR-Cas molecular tools and solution development services, centered on its proprietary ultra-compact Cas12l nuclease platform optimized for therapeutic delivery via adeno-associated viruses and for viral vector delivery in crops. The company combines deep bioinformatics/AI-driven discovery, protein engineering (rational design and directed evolution), biochemical characterization, and mRNA synthesis/optimization to deliver tailored gene editing solutions to partners in therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Revenue is generated through professional service engagements and licensing of proprietary Cas12l technology.

Product overview

CasZyme operates as a CRISPR technology platform company offering specialized services and proprietary nucleases. The core product is the Cas12l Platform featuring ultra-compact Cas12l nucleases optimized for therapeutic delivery. The service portfolio includes Custom CRISPR Solutions (end-to-end development from bioinformatics through verification), Nuclease Expertise (screening, purification, biochemical analysis), mRNA Synthesis and Optimization, and Protein Evolution. These offerings support five application areas: Therapeutics, Agri-Tech, Diagnostics, Research Tools, and Industrial Biotech. The company leverages over 15 years of CRISPR expertise to deliver market-ready products through a flexible, diverse platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cas12l Platform

Quantifiable outcome

  • 50%+ reduction in time and cost compared to traditional tissue culture approaches

Companies that use CasZyme

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles4 records

CasZyme technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

CasZyme partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • BetterSeedscoreStrategic or Co-development Partner · 13 April 2026CasZyme and BetterSeeds announced a collaboration to overcome the tissue culture bottleneck in plant gene editing by combining CasZyme's ultra-compact Cas12l nucleases with BetterSeeds' viral vector-based EDGE delivery platform. The partnership aims to eliminate or substantially reduce reliance on tissue culture, which is time-consuming, costly, and genotype-dependent, potentially cutting time and cost by more than 50% compared to traditional approaches.
  • Corteva AgrisciencecoreOEM/ Whitelabel/ Licensing Partner · 13 April 2026Corteva Agriscience has licensed Cas12l to both CasZyme and BetterSeeds, enabling viral delivery of gene edits directly into crops. This licensing arrangement makes CRISPR technology more accessible to a broader range of seed companies.
  • Vilnius University ConsortiumcoreStrategic or Co-development Partner · 1 April 2026Part of the EUREKA-Eurostars 3 project UNCOVER (Universal CRISPR-based Detection Platform for Versatile and Rapid Diagnostics) along with nSAGE and other partners. CasZyme is a member of the Vilnius University Consortium in the 'Implementation of Mission-Driven Science and Innovation Programmes' project focused on Innovations for Health.
  • VU (Vilnius University)minorStrategic or Co-development PartnerListed as a partner on CasZyme's website with logo displayed among other partner organizations. Vilnius University is also part of the consortium in EU grants.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

CasZyme competitors and assessment

Company assessment

Direct peers

  • Metagenomi: Metagenomi uses AI and metagenomic databases to discover novel CRISPR nuclease systems for therapeutic gene editing — the same core discovery thesis and methodology as CasZyme, but focused on human therapeutics development.
  • ToolGen: ToolGen is a Korea-based CRISPR tools company that discovers and licenses novel Cas nucleases for therapeutic and agricultural gene editing, overlapping with CasZyme's nuclease platform and licensing model.
  • Caribou Biosciences: Caribou Biosciences is a CRISPR platform company developing Cas nuclease-derived tools for both therapeutic and non-therapeutic applications, sharing CasZyme's platform-tools orientation and multi-vertical licensing approach.

Broad incumbents

  • Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing CRISPR-based therapeutics using its own proprietary nucleases; it represents a well-funded incumbent competing for the same therapeutic licensing and partnership opportunities CasZyme targets.
  • Editas Medicine: Editas Medicine is a clinical-stage gene editing company with proprietary Cas9 and Cas12a programs across therapeutic areas, operating as a broad incumbent in the same CRISPR therapeutics space as CasZyme.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene editing company with approved Cas9-based therapy (Casgevy), representing a well-capitalized incumbent in the therapeutic CRISPR market where CasZyme's nuclease IP could be licensed.
  • Beam Therapeutics: Beam Therapeutics develops base editing and prime editing therapeutics using proprietary enzymes, an adjacent gene editing modality that competes for the same therapeutic partnerships and licensing economics CasZyme targets.
  • New England Biolabs: NEB is a leading life science reagents and enzyme company that distributes research-use CRISPR tools, listed as a CasZyme partner. It represents a broad incumbent in the same research tools and nuclease distribution market.
  • Thermo Fisher Scientific: Thermo Fisher is a global life science tools and reagents giant with extensive gene editing and CRISPR product lines, listed as a CasZyme partner. It serves as a broad incumbent across the same customer base.

Emerging players

  • Inscripta (now part of Element Biosciences): Inscripta developed a CRISPR platform for gene editing and was acquired by Element Biosciences; it represents an emerging peer in CRISPR tools commercialization, with comparable nucleic acid manipulation focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CasZyme social profiles

Digital presence

CasZyme financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CasZyme leadership team

Management profile

Number of profiles

CasZyme funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CasZyme M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CasZyme

What does CasZyme do?

CasZyme develops and provides custom CRISPR-Cas molecular tools and solution development services, centered on its proprietary ultra-compact Cas12l nuclease platform optimized for therapeutic delivery via adeno-associated viruses and for viral vector delivery in crops. The company combines deep bioinformatics/AI-driven discovery, protein engineering (rational design and directed evolution), biochemical characterization, and mRNA synthesis/optimization to deliver tailored gene editing solutions to partners in therapeutics, agriculture, diagnostics, research tools, and industrial biotechnology. Revenue is generated through professional service engagements and licensing of proprietary Cas12l technology.

Is CasZyme a public or private company?

CasZyme is a private company. It is classified as unknown and is currently operating.

When was CasZyme founded?

CasZyme was founded in 2017. It employs 11 to 50 people.

Where is CasZyme based?

CasZyme is headquartered in Vilnius, Lithuania, in the Europe region.

How does CasZyme make money?

Two revenue lines are on record. Custom CRISPR Solutions Development is the primary driver. The others are licensing of Proprietary Technologies.

Who are CasZyme's main competitors?

Direct peers on record are Metagenomi, ToolGen and Caribou Biosciences. Broad incumbents are Intellia Therapeutics, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, New England Biolabs and Thermo Fisher Scientific. Inscripta (now part of Element Biosciences) is listed as an emerging player.

Does CasZyme have an API?

No public API is recorded for CasZyme.

What industry is CasZyme in?

CasZyme's product category is CRISPR Gene Editing Tools and Services. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l PerformanceCasZyme and Cirena signed an agreement to optimize Cas12l editing efficiency using Cirena's synthetic 150-170 nt guide RNAs. The collaboration targets CAR-T and LNP-based therapies, with editing results expected in early 2027.GlobeNewswireCasZyme and Cirena to Collaborate on Developing Longer Guide RNAs to Optimise Cas12l PerformanceCasZyme and Cirena signed an agreement to optimize Cas12l editing efficiency using Cirena's synthetic 150-170 nt guide RNAs. The collaboration targets CAR-T and LNP-based therapies, with editing results expected in early 2027.AgtechnavigatorBetterSeeds and Caszyme target tissue culture bottleneck with viral delivery of ultra‑compact CRISPR toolsBetterSeeds and Caszyme have announced a collaboration to overcome the tissue culture bottleneck in plant gene editing by combining Caszyme's ultra-compact Cas12l nucleases with BetterSeeds' viral vector-based EDGE delivery platform. The partnership aims to eliminate or substantially reduce reliance on tissue culture, which is time-consuming, costly, and genotype-dependent, potentially cutting time and cost by more than 50% compared to traditional approaches. The companies also announced that Corteva Agriscience has licensed Cas12l to both partners, enabling viral delivery of gene edits directly into crops to make CRISPR technology more accessible to a broader range of seed companies.GenengnewsLithuania Focused on Building a World-Leading Life Science SectorLithuania is building a world-leading life science sector, with startups like Delta Biosciences and Caszyme developing biotech tools. The country's life science sector contributes about 2.5% of GDP, aiming to reach 5% by 2030, and Thermo Fisher's Vilnius site employs 1,850 people. Startups are seeking European venture capital investment.PR NewswireNew England Biolabs® and CasZyme collaborate to enable genome editing applications with novel Cas9 EnzymesNew England Biolabs and CasZyme announced a multi-year collaboration to identify, characterize, and commercialize novel CRISPR-Cas nucleases for genome editing applications. Under the agreement, CasZyme will apply its enzymology expertise to discover these enzymes, while New England Biolabs will manufacture them for global distribution.PrwebDuPont Pioneer and CasZyme Collaborating to Advance New CRISPR-Cas Gene-Editing ToolsDuPont Pioneer and CasZyme announced a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. Pioneer will provide its CRISPR-Cas library, while CasZyme applies biochemical assays to characterize the nucleases. Specific financial terms were not disclosed.